BR112015023699A2 - método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo - Google Patents

método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo

Info

Publication number
BR112015023699A2
BR112015023699A2 BR112015023699A BR112015023699A BR112015023699A2 BR 112015023699 A2 BR112015023699 A2 BR 112015023699A2 BR 112015023699 A BR112015023699 A BR 112015023699A BR 112015023699 A BR112015023699 A BR 112015023699A BR 112015023699 A2 BR112015023699 A2 BR 112015023699A2
Authority
BR
Brazil
Prior art keywords
pulmonary disease
fibrotic pulmonary
determining
fibrotic
patient
Prior art date
Application number
BR112015023699A
Other languages
English (en)
Portuguese (pt)
Inventor
Ruhrmund Donald
Kossen Karl
R Lim Sharleen
D Seiwert Scott
Qin Xiaoli
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of BR112015023699A2 publication Critical patent/BR112015023699A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
BR112015023699A 2013-03-15 2014-03-14 método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo BR112015023699A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361801290P 2013-03-15 2013-03-15
US201361801476P 2013-03-15 2013-03-15
US201361874947P 2013-09-06 2013-09-06
PCT/US2014/029392 WO2014144821A1 (en) 2013-03-15 2014-03-14 Proteomic ipf markers

Publications (1)

Publication Number Publication Date
BR112015023699A2 true BR112015023699A2 (pt) 2017-07-18

Family

ID=51537804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023699A BR112015023699A2 (pt) 2013-03-15 2014-03-14 método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo

Country Status (11)

Country Link
US (1) US9726677B2 (https=)
EP (1) EP2972392A4 (https=)
JP (1) JP2016519763A (https=)
KR (1) KR20150130408A (https=)
CN (1) CN105122068A (https=)
BR (1) BR112015023699A2 (https=)
CA (1) CA2901384A1 (https=)
HK (1) HK1219533A1 (https=)
MX (1) MX2015012778A (https=)
RU (1) RU2015144149A (https=)
WO (1) WO2014144821A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
HK1219533A1 (zh) 2013-03-15 2017-04-07 Intermune, Inc. 蛋白质组学ipf标志物
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension
CN110945128B (zh) * 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 用于治疗肺纤维化的组合物和方法
CN107677835B (zh) * 2017-09-26 2019-08-09 上海市肺科医院 一种ae-ipf的蛋白标记物及其应用
BR112021002728A2 (pt) * 2018-08-17 2021-08-10 F. Hoffmann-La Roche Ag métodos de avaliação da fibrilação atrial, de auxílio à avaliação da fibrilação atrial, de diagnóstico de insuficiência cardíaca e de predição do risco de hospitalização, método implementado por computador para a avaliação da fibrilação atrial, kit e usos in vitro
EP3875958A4 (en) * 2018-10-29 2022-10-05 National University Corporation Tokyo Medical and Dental University Method for obtaining information on risk of reduced respiratory function in patient with interstitial pneumonia, and use thereof
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN110333358A (zh) * 2019-06-24 2019-10-15 浙江大学 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法
WO2021024856A1 (ja) * 2019-08-02 2021-02-11 国立医薬品食品衛生研究所長が代表する日本国 間質性肺炎のタンパク質診断バイオマーカー
CA3171622A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
WO2021210651A1 (ja) * 2020-04-17 2021-10-21 国立医薬品食品衛生研究所長が代表する日本国 重症薬疹のタンパク質診断バイオマーカー
CN113607955A (zh) * 2020-09-16 2021-11-05 广州中医药大学顺德医院(佛山市顺德区中医院) 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用
CN113533750A (zh) * 2020-10-22 2021-10-22 广州中医药大学顺德医院(佛山市顺德区中医院) 一种区分新型冠状病毒肺炎患者与健康者的系统
WO2023038416A1 (ko) * 2021-09-07 2023-03-16 주식회사 에프엔씨티바이오텍 폐 섬유증의 바이오마커 및 치료 표적으로서 csf3r
US20230147720A1 (en) * 2021-11-05 2023-05-11 Spiritus Therapeutics, Inc. Purified Enriched Population Exosomes Derived From Individuals With A Chronic Progressive Lung Disease For Noninvasive Detection, Staging, And Medical Monitoring Of Disease Progression
CN114563562A (zh) * 2022-03-01 2022-05-31 复旦大学附属中山医院 Prdx6联合铁离子检测在ards进程监测中的应用
KR102907646B1 (ko) * 2022-08-19 2026-01-05 울산대학교 산학협력단 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커
CN119947728A (zh) * 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
CN117025745B (zh) * 2022-11-18 2024-02-23 中国医学科学院北京协和医院 分子标志物在诊断干燥综合征中的应用
WO2026069490A1 (ja) * 2024-09-25 2026-04-02 国立大学法人大阪大学 進行性肺線維症診断用バイオマーカー、該バイオマーカーを用いた進行性肺線維症の検査方法及びそれらの利用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6019988A (en) * 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
AU2002307494A1 (en) * 2001-04-24 2002-11-05 Bayer Corporation Human timp-1 antibodies
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1626279B1 (en) * 2004-08-12 2008-04-16 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
CN101160528A (zh) * 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
WO2009028158A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
US8568996B2 (en) * 2008-10-21 2013-10-29 University of Pittsburgh—of the Commonwealth System of Higher Education MMP activation peptide detection in biological samples
US20110280865A1 (en) * 2009-01-16 2011-11-17 The Ohio State University Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof
WO2010102167A1 (en) * 2009-03-05 2010-09-10 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010111625A1 (en) * 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
NZ625850A (en) * 2009-08-21 2015-12-24 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
US20120282276A1 (en) * 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
WO2011091270A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of Michigan Biomarkers for lung disease monitoring
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
HK1219533A1 (zh) 2013-03-15 2017-04-07 Intermune, Inc. 蛋白质组学ipf标志物

Also Published As

Publication number Publication date
MX2015012778A (es) 2016-01-20
EP2972392A1 (en) 2016-01-20
CA2901384A1 (en) 2014-09-18
KR20150130408A (ko) 2015-11-23
CN105122068A (zh) 2015-12-02
JP2016519763A (ja) 2016-07-07
HK1219533A1 (zh) 2017-04-07
EP2972392A4 (en) 2017-03-22
RU2015144149A (ru) 2017-04-21
WO2014144821A1 (en) 2014-09-18
US9726677B2 (en) 2017-08-08
US20140286929A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112015023699A2 (pt) método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo
BR112012025593A2 (pt) biomarcadores em circulação para doença
WO2015176066A3 (en) Lpa-associated protein and rna expression
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
HUE055002T2 (hu) Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra
HUE049237T2 (hu) Készítmények a bõr sérülései, rendellenességei és betegségei kezelési eljárásaiban történõ alkalmazásra
BR112013031673A2 (pt) dispositivo de fio-guia configurado para avaliar um ou mais lúmens corporais vasculares
EP3468356A4 (en) GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
EP3362060A4 (en) BIOMARKERS FOR DIABETES AND TREATMENT OF DIABETES-BASED ILLNESSES
IL284414A (en) Methods and compositions for the treatment of fabry disease
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
EP3661527A4 (en) MULTI-BIOMARKER DISEASE ACTIVITY SCORE ADJUSTED TO ASSESS INFLAMMATORY DISEASE
MX377154B (es) Polimeros de union a protones para administracion oral.
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
BR112017014419A2 (pt) diagnose e tratamento de diabetes incipiente
BR112016005832A2 (pt) Controle biológico de insetos
EP3356832A4 (en) BIOMARKERS AND METHOD FOR ASSESSING THE DISEASE ACTIVITY OF PSORIASIS TARTHRITIS
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112017008805A2 (pt) tratamento de córnea usando laminina
PL3678649T3 (pl) Donosowe formulacje epinefryny i sposoby leczenia choroby
BR112015022025A2 (pt) método de tratamento de infecções, doenças ou desordens de unidade de unha

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)